

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BOUGUELERET ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/007047

FILED: 29 JUNE 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH
CARDIOVASCULAR DISORDERS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the restriction requirement of June 5, 2008, Applicants hereby elect Group 1, claims 1-7, drawn to a method of screening for and/or diagnosis of a cardiovascular disorder in a subject.

This election is made with traverse. Applicants respectfully request a rejoinder of Groups 2-5, insofar as they apply to SEQ ID NO:3, since the screening and diagnosis methods of Group 1 directly implicate CPP (Cardiovascular disorder Plasma Polypeptides) polypeptides and anti-CPP antibodies. In the search for said screening and diagnosis methods in the art, the Examiner will inevitably be looking for CPP polypeptides and anti-CPP antibodies that can potentially be used to detect, e.g., SEQ ID NO: 3.

Applicants file a three month petition for extension of time herewith, and believe that no additional fees are due with this filing. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 504409 in the name of Novartis for any fees due.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

Novartis Institutes for Biomedical Research, Inc.
400 Technology Square
Cambridge MA 02139

(617) 871-3343
Date: October 6, 2008

/Paul J. Paglierani/
Paul J. Paglierani
Attorney for Applicants
Reg. No. 52,498

